100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year

Trump Administration’s surprising call for increased user fees probably won’t have much impact on pending reauthorization process, but it does put on the table an important question for the biopharma industry to consider for the long term: should FDA be fully funded by user fees?